



Antibiotic Resistance and Intensive Care Unit

Guest Editors:

Dr. Giancarlo Ceccarelli

Department of Public Health and
Infectious Diseases, Sapienza
University of Rome, Rome, Italy

Dr. Francesco Alessandri

Assistant Professor, Department
of Anesthesia, Critical Care and
Pain Medicine, Sapienza
University of Rome, Rome, Italy

Deadline for manuscript
submissions:

closed (12 August 2021)

Message from the Guest Editors

Dear Colleagues,

More than one-third of intensive care unit (ICU) patients develop an infection during their stay and antibiotic resistance is a serious challenge in the treatment of such conditions. Of particular concern is the misuse or overuse of antibiotics, which has led to the development of resistant or super-resistant bacterial strains. Minimization of broad-spectrum antibiotic use and prompt antibiotic administration aid in the reduction of antibiotic resistance. However, areas where further research is required are investigation into the heterogeneity of critically ill patients and the need for new antibacterial drug development. The purpose of this Special Issue of *Antibiotics* is to present a collection of the latest high quality research in this field, with a particular focus on antibiotic therapy against multidrug resistant bacteria in intensive care patients.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciplines are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPUS / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)